<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> often lose human leukocyte antigen (HLA) class I expression </plain></SENT>
<SENT sid="1" pm="."><plain>The outgrowth of clones with immune evasive phenotypes is thought to be positively selected by the action of cytotoxic T cells that target HLA class I-positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>To investigate this hypothesis, we related the type and density of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lymphocytic infiltrate in Lynch <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> with their HLA class I phenotype and clinicopathologic stage </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: HLA class I expression was assessed by means of immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>Characterization of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-infiltrating lymphocytes was carried out by using a triple immunofluorescence procedure that allowed the simultaneous detection of CD3-, CD8-, and granzyme B (GZMB)-positive cells </plain></SENT>
<SENT sid="5" pm="."><plain>Additional markers were also used for further characterization of an elusive CD3(-)/CD8(-)/GZMB(+) cell population </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: We discovered that high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltration by activated CD8(+) T cells correlated with aberrant HLA class I expression and associated with early <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stages (P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>CD8(+) T cells were most abundant in HLA class I <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (P = 0.02) and frequent in HLA class I-negative cases (P = 0.04) when compared with HLA class I-positive <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>An elusive immune cell population (CD45(+)/CD8(-)/CD56(-)/GZMB(+)) was characteristic for HLA class I-negative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> lacking <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> (P &lt; 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The immune system assumes an important role in counteracting the progression of Lynch <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> and in selecting abnormal HLA class I phenotypes </plain></SENT>
<SENT sid="10" pm="."><plain>Our findings support the development of clinical strategies that explore the natural antitumor immune responses occurring in <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> carriers </plain></SENT>
</text></document>